Scott Power

I thought I'd look at a couple of the emerging healthcare names with near-term catalysts, specifically some quarterly sales that are going to be reported in January. They're not formally covered, but Derek Jellinek and I have had the opportunity to meet with management over the last month, and we've... Show More

Stuart Roberts

A year ago it looked like disaster had struck Osprey Medical. In June 2014 the company had gained FDA approval for AVERT, a system that reduces the amount of contrast dye interventional cardiologists use during heart procedures. Contrast dye lets cardiologists see what's going on under X-Ray, but can be... Show More

Mitch Taylor

An ASX listed medical device company with big upside. OSP's FDA approved DyeVert device reduces the amount of contrast iodine injected into patients undergoing common heart and peripheral vascular procedures such as angioplasty and stenting. Show More